VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Stock Comparison

Agilent Technologies, Inc. vs GSK plc

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Agilent Technologies, Inc.

A · New York Stock Exchange

Market cap (USD)$34.8B
Gross margin (TTM)52.4%
Operating margin (TTM)21.3%
Net margin (TTM)18.8%
SectorHealthcare
IndustryMedical - Diagnostics & Research
CountryUS
Data as of2025-12-22
Moat score
65/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Agilent Technologies, Inc.'s moat claims, evidence, and risks.

View A analysis

GSK plc

GSK · London Stock Exchange

Market cap (USD)$89.3B
Gross margin (TTM)72.5%
Operating margin (TTM)22%
Net margin (TTM)17.5%
SectorHealthcare
IndustryDrug Manufacturers - General
CountryGB
Data as of2025-12-28
Moat score
62/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into GSK plc's moat claims, evidence, and risks.

View GSK analysis

Comparison highlights

  • Moat score gap: Agilent Technologies, Inc. leads (65 / 100 vs 62 / 100 for GSK plc).
  • Segment focus: Agilent Technologies, Inc. has 3 segments (41.9% in Agilent CrossLab); GSK plc has 3 segments (37.6% in Specialty Medicines).
  • Primary market structure: Competitive vs Oligopoly. Pricing power: Strong vs Strong.
  • Moat breadth: Agilent Technologies, Inc. has 5 moat types across 2 domains; GSK plc has 4 across 3.

Primary market context

Agilent Technologies, Inc.

Agilent CrossLab

Market

Laboratory services, compliance/maintenance, consumables and lab informatics across the lab workflow

Geography

Global

Customer

B2B (installed base labs across pharma, diagnostics, academia and applied markets)

Role

Aftermarket services + consumables + informatics

Revenue share

41.9%

GSK plc

Specialty Medicines

Market

Branded specialty pharmaceuticals (HIV, oncology, immunology/respiratory)

Geography

Global

Customer

Hospitals, specialist physicians, payers

Role

Innovator & branded manufacturer

Revenue share

37.6%

Side-by-side metrics

Agilent Technologies, Inc.
GSK plc
Ticker / Exchange
A - New York Stock Exchange
GSK - London Stock Exchange
Market cap (USD)
$34.8B
$89.3B
Gross margin (TTM)
52.4%
72.5%
Operating margin (TTM)
21.3%
22%
Net margin (TTM)
18.8%
17.5%
Sector
Healthcare
Healthcare
Industry
Medical - Diagnostics & Research
Drug Manufacturers - General
HQ country
US
GB
Primary segment
Agilent CrossLab
Specialty Medicines
Market structure
Competitive
Oligopoly
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Strong
Strong
Moat score
65 / 100
62 / 100
Moat domains
Demand, Supply
Supply, Legal, Demand
Last update
2025-12-22
2025-12-28

Moat coverage

Shared moat types

No overlap yet.

Agilent Technologies, Inc. strengths

Design In QualificationInstalled Base ConsumablesBrand TrustService Field NetworkData Workflow Lockin

GSK plc strengths

Capex Knowhow ScaleCompliance AdvantageIP Choke PointSwitching Costs General

Segment mix

Agilent Technologies, Inc. segments

Full profile >

Life Sciences and Diagnostics Markets

Oligopoly

39.2%

Agilent CrossLab

Competitive

41.9%

Applied Markets

Oligopoly

18.9%

GSK plc segments

Full profile >

Vaccines

Oligopoly

29.1%

Specialty Medicines

Oligopoly

37.6%

General Medicines

Competitive

33.2%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.